{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:51:48Z","timestamp":1781657508110,"version":"3.54.5"},"reference-count":106,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Rare bone diseases (RBDs) may display a disrupted RANKL-RANK-osteoprotegerin pathway causing increased osteoclastogenesis and enhanced bone resorption. Although bisphosphonates are commonly used, they often fall short of desired outcomes. Denosumab, an anti-RANKL antibody, provides a promising alternative by swiftly and strongly suppressing bone turnover (faster and more potent suppression of bone resorption than bisphosphonates), though its effects are reversible on discontinuation. The use of denosumab has been highlighted, especially in pediatric cases, but not substantially in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence Acquisition<\/jats:title>\n                    <jats:p>A targeted evidence search was conducted to retrieve studies reporting denosumab use in RBDs in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence Synthesis<\/jats:title>\n                    <jats:p>Denosumab administration may lead to pain reduction, lesion reduction, or bone formation. Treatment dosage, schedules, and duration varied, however, a dose of 120 mg dosed monthly or every 3 months for almost 1 year reached the desired treatment effect in most patients. Denosumab is generally well tolerated in adults, with mild common side effects such as (asymptomatic) hypocalcemia and hypophosphatemia. Serious adverse effects such as osteonecrosis of the jaw or atypical femoral fractures are rarely reported. Main concerns regard rebound effect after denosumab discontinuation, with disease recurrence in some cases. Zoledronic acid after discontinuation of denosumab might be advisable, but is seldom reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Denosumab is a feasible treatment in adults with RBDs when managed by multidisciplinary teams with knowledge of both the underlying disease and potential surgeries as well as the medical site of treatment. Denosumab discontinuation management is paramount to prevent recurrence and severe complications. The paucity of data supports the need for data collection through rare disease registries for future pertinent evidence-based recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag154","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T20:06:09Z","timestamp":1775765169000},"page":"e1760-e1773","source":"Crossref","is-referenced-by-count":0,"title":["The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8171-7253","authenticated-orcid":false,"given":"Oana O","family":"Bulaicon","sequence":"first","affiliation":[{"name":"Center for Bone Quality, Leiden University Medical Center , 2333 ZA Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9551-9064","authenticated-orcid":false,"given":"Femke M","family":"van Haalen","sequence":"additional","affiliation":[{"name":"Center for Bone Quality, Leiden University Medical Center , 2333 ZA Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8411-0685","authenticated-orcid":false,"given":"Gavin P R","family":"Clunie","sequence":"additional","affiliation":[{"name":"Metabolic Bone Physician, Cambridge University Hospitals , Box 204, Hills Rd, Cambridge CB2 0QQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1793-4603","authenticated-orcid":false,"given":"Corinna","family":"Grasemann","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Katholisches Klinikum Bochum, Ruhr-University Bochum , Bochum 44791, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-3953","authenticated-orcid":false,"given":"Willem F","family":"Lems","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam University Medical Center , 1105 AZ Amsterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3357","authenticated-orcid":false,"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[{"name":"LCH Adult Clinic, Department of Medical Research, and Department of Endocrinology and Diabetes, 251 Hellenic Air Force and VA General Hospital , Athens 11525 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9871-4578","authenticated-orcid":false,"given":"Geert","family":"Mortier","sequence":"additional","affiliation":[{"name":"Center for Human Genetics, University Hospital Leuven and KU Leuven , Leuven B-3000 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-5013","authenticated-orcid":false,"given":"Ralf","family":"Oheim","sequence":"additional","affiliation":[{"name":"Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf , Hamburg 22529 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3551-594X","authenticated-orcid":false,"given":"Adalbert","family":"Raimann","sequence":"additional","affiliation":[{"name":"Department of Pediatrics & Adolescent Medicine, Vienna Bone and Growth Center, Medical University Vienna , Vienna 1090 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8366-8625","authenticated-orcid":false,"given":"Heide","family":"Siggelkow","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center G\u00f6ttingen , G\u00f6ttingen 37075 ,","place":["Germany"]},{"name":"MVZ Endokrinologikum G\u00f6ttingen , G\u00f6ttingen 37075 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-0700","authenticated-orcid":false,"given":"Gaia","family":"Tabacco","sequence":"additional","affiliation":[{"name":"Unit of Metabolic Bone and Thyroid Disorders, Fondazione Policlinico Universitario Campus Bio-Medico , Rome 00128 ,","place":["Italy"]},{"name":"Department for the Promotion of Human Sciences and Quality of Life, San Raffaele Open University , Rome 00166 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8724-7692","authenticated-orcid":false,"given":"Robert J P","family":"van der Wal","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Leiden University Medical Center , 2333 ZA Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9550-1630","authenticated-orcid":false,"given":"Pieter B","family":"de Witte","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Leiden University Medical Center , 2333 ZA Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-127X","authenticated-orcid":false,"given":"Natasha M","family":"Appelman-Dijkstra","sequence":"additional","affiliation":[{"name":"Center for Bone Quality, Leiden University Medical Center , 2333 ZA Leiden ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"5","key":"2026061619565620300_dgag154-B1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beem.2008.07.006","article-title":"Bone remodelling: its local regulation and the emergence of bone fragility","volume":"22","author":"Martin","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2026061619565620300_dgag154-B2","first-page":"1587","article-title":"Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation","volume":"151","author":"Riminucci","year":"1997","journal-title":"Am J Pathol"},{"issue":"1","key":"2026061619565620300_dgag154-B3","first-page":"297","article-title":"The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts","volume":"16","author":"Zheng","year":"2001","journal-title":"Histol Histopathol"},{"issue":"1","key":"2026061619565620300_dgag154-B4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00774-020-01148-4","article-title":"Genetic disorders associated with the RANKL\/OPG\/RANK pathway","volume":"39","author":"Xue","year":"2021","journal-title":"J Bone Miner Metab"},{"issue":"12","key":"2026061619565620300_dgag154-B5","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/jbmr.3828","article-title":"RANKL inhibition in fibrous dysplasia of bone: a preclinical study in a mouse model of the human disease","volume":"34","author":"Palmisano","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026061619565620300_dgag154-B6","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMc2214862","article-title":"Safety and efficacy of denosumab for fibrous dysplasia of bone","volume":"388","author":"de Castro","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"2026061619565620300_dgag154-B7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.trsl.2014.03.005","article-title":"Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response","volume":"164","author":"Pelle","year":"2014","journal-title":"Transl Res"},{"issue":"7","key":"2026061619565620300_dgag154-B8","doi-asserted-by":"crossref","first-page":"R246","DOI":"10.1530\/EC-18-0186","article-title":"Bone metabolism in langerhans cell histiocytosis","volume":"7","author":"Anastasilakis","year":"2018","journal-title":"Endocr Connect"},{"issue":"S1","key":"2026061619565620300_dgag154-B9","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1186\/1750-1172-7-S1-S6","article-title":"Cherubism: best clinical practice","volume":"7","author":"Papadaki","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2026061619565620300_dgag154-B10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13023-014-0200-y","article-title":"Hajdu-Cheney syndrome: a review","volume":"9","author":"Canalis","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2026061619565620300_dgag154-B11","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1210\/clinem\/dgad657","article-title":"Management of RANKL-mediated disorders with denosumab in children and adolescents: a global expert guidance document","volume":"109","author":"Vanderniet","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026061619565620300_dgag154-B12","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease","volume":"353","author":"Reid","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2026061619565620300_dgag154-B13","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1210\/jc.2003-030050","article-title":"Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone","volume":"88","author":"Plotkin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026061619565620300_dgag154-B14","first-page":"3109","article-title":"Cherubism: a case report with surgical intervention","volume":"36","author":"Friedrich","year":"2016","journal-title":"Anticancer Res"},{"issue":"2","key":"2026061619565620300_dgag154-B15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"issue":"3","key":"2026061619565620300_dgag154-B16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"2026061619565620300_dgag154-B17","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"2026061619565620300_dgag154-B18","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"2026061619565620300_dgag154-B19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1530\/EJE-16-1027","article-title":"Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment","volume":"176","author":"Anastasilakis","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026061619565620300_dgag154-B20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2026061619565620300_dgag154-B21","unstructured":"Bulaicon O, Clunie GPR, Grasemann C, et al \u00a0Data from: The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group. doi:10.6084\/m9.figshare.31839388"},{"issue":"1","key":"2026061619565620300_dgag154-B22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archsurg.1948.01240020140011","article-title":"Solitary, unicameral, bone cyst","volume":"57","author":"James","year":"1948","journal-title":"Arch Surg (1920)"},{"key":"2026061619565620300_dgag154-B23","first-page":"176","article-title":"Aneurysmal bone cyst. A population based epidemiologic study and literature review","volume":"363","author":"Leithner","year":"1999","journal-title":"Clin Orthop Relat Res"},{"key":"2026061619565620300_dgag154-B24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jocn.2022.03.040","article-title":"Aneurysmal bone cyst of the spine in adult patients: a systematic review and comparison of primary vs secondary lesions","volume":"100","author":"Palmisciano","year":"2022","journal-title":"J Clin Neurosci"},{"issue":"1","key":"2026061619565620300_dgag154-B25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JCO.2005.04.4818","article-title":"Aneurysmal bone cyst: a neoplasm driven by upregulation of the USP6 oncogene","volume":"24","author":"Oliveira","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026061619565620300_dgag154-B26","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12178-016-9371-6","article-title":"Current management of aneurysmal bone cysts","volume":"9","author":"Park","year":"2016","journal-title":"Curr Rev Musculoskelet Med"},{"issue":"3","key":"2026061619565620300_dgag154-B27","doi-asserted-by":"crossref","first-page":"10225536241297105","DOI":"10.1177\/10225536241297105","article-title":"Exploring Denosumab\u2019s potential in aneurysmal bone cyst treatment: a scoping review","volume":"32","author":"Sandhu","year":"2024","journal-title":"J Orthop Surg (Hong Kong)"},{"issue":"22","key":"2026061619565620300_dgag154-B28","doi-asserted-by":"crossref","first-page":"E1201","DOI":"10.1097\/BRS.0000000000001027","article-title":"Response of aneurysmal bone cyst to denosumab","volume":"40","author":"Skubitz","year":"2015","journal-title":"Spine (Phila Pa 1976)"},{"key":"2026061619565620300_dgag154-B29","first-page":"9125493","article-title":"Therapeutic management of a substantial pelvic aneurysmatic bone cyst including the off-label use of denosumab in a 35-year-old female patient","volume":"2017","author":"Ntalos","year":"2017","journal-title":"Case Rep Orthop"},{"issue":"12","key":"2026061619565620300_dgag154-B30","doi-asserted-by":"crossref","first-page":"E107","DOI":"10.1002\/hed.25438","article-title":"Massive aneurysmal bone cyst of the skull base treated with denosumab","volume":"40","author":"Asi","year":"2018","journal-title":"Head Neck"},{"issue":"1","key":"2026061619565620300_dgag154-B31","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s12891-019-2855-y","article-title":"Aneurysmal bone cyst: results of an off label treatment with denosumab","volume":"20","author":"D\u00fcrr","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"2026061619565620300_dgag154-B32","first-page":"e39954","article-title":"The efficacy of denosumab in treating spinal aneurysmal bone cyst: a case report","volume":"15","author":"Kotaka","year":"2023","journal-title":"Cureus"},{"issue":"17","key":"2026061619565620300_dgag154-B33","doi-asserted-by":"crossref","first-page":"e37870","DOI":"10.1097\/MD.0000000000037870","article-title":"Erdheim-Chester disease as complex clinical presentation and diagnosis: a case report and concise review of literature","volume":"103","author":"Gagliardo","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"15","key":"2026061619565620300_dgag154-B34","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.3390\/jcm13154522","article-title":"Denosumab re-challenge and long-term efficacy for aneurysmal bone cyst of the spine. Enhanced treatment algorithm","volume":"13","author":"Evangelisti","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"2026061619565620300_dgag154-B35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4055\/cios22228","article-title":"Using denosumab as a nonsurgical management of aneurysmal bone cysts in the pelvis","volume":"16","author":"El Masry","year":"2024","journal-title":"Clin Orthop Surg"},{"issue":"1","key":"2026061619565620300_dgag154-B36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0030-4220(53)90151-0","article-title":"Giant-cell reparative granuloma, traumatic bone cyst, and fibrous (fibro-oseous) dysplasia of the jawbones","volume":"6","author":"Jaffe","year":"1953","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"9","key":"2026061619565620300_dgag154-B37","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ijom.2006.03.030","article-title":"Calcitonin therapy in central giant cell granuloma of the jaw: a randomized double-blind placebo-controlled study","volume":"35","author":"de Lange","year":"2006","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"8","key":"2026061619565620300_dgag154-B38","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/jop.12730","article-title":"Central giant cell lesion of the jaws: an updated analysis of 2270 cases reported in the literature","volume":"47","author":"Chrcanovic","year":"2018","journal-title":"J Oral Pathol Med"},{"issue":"5","key":"2026061619565620300_dgag154-B39","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/j.oooo.2015.07.011","article-title":"Aggressive giant cell lesion of the jaws: a review of management options and report of a mandibular lesion treated with denosumab","volume":"120","author":"O'Connell","year":"2015","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"2","key":"2026061619565620300_dgag154-B40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/path.5365","article-title":"Making sense of giant cell lesions of the jaws (GCLJ): lessons learned from next-generation sequencing","volume":"250","author":"Gomes","year":"2020","journal-title":"J Pathol"},{"issue":"10","key":"2026061619565620300_dgag154-B41","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/j.bjoms.2020.07.032","article-title":"Intralesional injection of triamcinolone hexacetonide as an alternative treatment for central giant cell lesions: a prospective study","volume":"58","author":"Nogueira","year":"2020","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"SUPPL. 1","key":"2026061619565620300_dgag154-B42","article-title":"Denosumab an innovative and effective treatment for giant cell reparative granuloma","volume":"28","author":"Gomez","year":"2013","journal-title":"J Bone Miner Res Conf"},{"issue":"3","key":"2026061619565620300_dgag154-B43","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10006-024-01245-y","article-title":"Denosumab as treatment of central giant cell granuloma of the jaws. a scoping review","volume":"28","author":"Latorre","year":"2024","journal-title":"Oral Maxillofac Surg"},{"issue":"9","key":"2026061619565620300_dgag154-B44","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jcms.2025.05.012","article-title":"Novel approach to central giant cell granuloma of the jaw: low-dose intralesional denosumab treatment in a case series of nine patients","volume":"53","author":"Hassing","year":"2025","journal-title":"J Craniomaxillofac Surg"},{"issue":"4","key":"2026061619565620300_dgag154-B45","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijom.2025.10.004","article-title":"Treatment of central giant cell granuloma of the jaws with intralesional denosumab: initial report","volume":"55","author":"Jolly","year":"2026","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"4","key":"2026061619565620300_dgag154-B46","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00223-021-00935-z","article-title":"Clinical and radiologic response of central giant cell granuloma to denosumab: a 6-year prospective observational study","volume":"110","author":"Rhou","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"2026061619565620300_dgag154-B47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejca.2022.08.011","article-title":"RANKL inhibition for giant cell lesions of the jaw: a retrospective cohort analysis","volume":"175","author":"Schreuder","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"2026061619565620300_dgag154-B48","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00784-021-04193-z","article-title":"Non-surgical treatment as an alternative for the management of central giant cell granuloma: a systematic review","volume":"26","author":"Camarini","year":"2022","journal-title":"Clin Oral Investig"},{"issue":"2","key":"2026061619565620300_dgag154-B49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/ams.ams_192_18","article-title":"Denosumab treatment for aggressive multiple recurrent familial central giant-cell granulomas","volume":"8","author":"Rytk\u00f6nen","year":"2018","journal-title":"Ann Maxillofac Surg"},{"issue":"1","key":"2026061619565620300_dgag154-B50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijom.2020.05.021","article-title":"Cherubism: a systematic literature review of clinical and molecular aspects","volume":"50","author":"Chrcanovic","year":"2021","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"Suppl 1","key":"2026061619565620300_dgag154-B51","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1750-1172-7-S1-S5","article-title":"The role of SH3BP2 in the pathophysiology of cherubism","volume":"7","author":"Reichenberger","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2026061619565620300_dgag154-B52","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1097\/SCS.0b013e3181ecc529","article-title":"Postpubertal nonfamilial cherubism and teeth transposition","volume":"21","author":"Ozan","year":"2010","journal-title":"J Craniofac Surg"},{"issue":"1","key":"2026061619565620300_dgag154-B53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7181\/acfs.2023.00577","article-title":"Surgical management of severe cherubism persisting into early adulthood: a case report and literature review","volume":"25","author":"Choi","year":"2024","journal-title":"Arch Craniofac Surg"},{"issue":"10","key":"2026061619565620300_dgag154-B54","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/S0161-6420(01)00757-6","article-title":"Orbital involvement in cherubism","volume":"108","author":"Colombo","year":"2001","journal-title":"Ophthalmology"},{"issue":"6","key":"2026061619565620300_dgag154-B55","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/thorax.58.6.552","article-title":"Sleep disordered breathing in an adult with cherubism","volume":"58","author":"Ladhani","year":"2003","journal-title":"Thorax"},{"issue":"12","key":"2026061619565620300_dgag154-B56","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/jbmr.4922","article-title":"Efficacy and toxicity of calcitonin treatment in children with cherubism: a single-center cohort study","volume":"38","author":"Schreuder","year":"2023","journal-title":"J Bone Miner Res"},{"key":"2026061619565620300_dgag154-B57","doi-asserted-by":"crossref","first-page":"1104025","DOI":"10.3389\/fendo.2023.1104025","article-title":"Pharmacological management of cherubism: a systematic review","volume":"14","author":"Cailleaux","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2026061619565620300_dgag154-B58","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/j.joms.2020.06.016","article-title":"Positive outcomes of denosumab treatment in 2 patients with cherubism","volume":"78","author":"Bar Droma","year":"2020","journal-title":"J Oral Maxillofac Surg"},{"issue":"2","key":"2026061619565620300_dgag154-B59","doi-asserted-by":"crossref","first-page":"ziae164","DOI":"10.1093\/jbmrpl\/ziae164","article-title":"Successful treatment of adult cherubism with a 60 mg denosumab 6-monthly regimen","volume":"9","author":"Le","year":"2025","journal-title":"JBMR Plus"},{"issue":"3","key":"2026061619565620300_dgag154-B60","first-page":"750","article-title":"An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome","volume":"79","author":"Shenker","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026061619565620300_dgag154-B61","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/endrev\/bnz011","article-title":"Fibrous dysplasia\/McCune-Albright syndrome: a rare, mosaic disease of G\u03b1s activation","volume":"41","author":"Boyce","year":"2020","journal-title":"Endocr Rev"},{"issue":"Suppl 1","key":"2026061619565620300_dgag154-B62","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1750-1172-7-S1-S4","article-title":"McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia","volume":"7","author":"Collins","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2026061619565620300_dgag154-B63","first-page":"818","article-title":"The correlation of specific orthopaedic features of polyostotic fibrous dysplasia with functional outcome scores in children","volume":"88","author":"Leet","year":"2006","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"2026061619565620300_dgag154-B64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"2026061619565620300_dgag154-B65","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2026061619565620300_dgag154-B66","doi-asserted-by":"crossref","first-page":"101058","DOI":"10.1016\/j.bonr.2021.101058","article-title":"Regression of fibrous dysplasia in response to denosumab therapy: a report of two cases","volume":"14","author":"Meier","year":"2021","journal-title":"Bone Rep"},{"issue":"3","key":"2026061619565620300_dgag154-B67","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.3390\/ijms24032550","article-title":"Pharmacological interventions targeting pain in fibrous dysplasia\/McCune-Albright syndrome","volume":"24","author":"Tucker-Bartley","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2026061619565620300_dgag154-B68","doi-asserted-by":"crossref","first-page":"E2980","DOI":"10.1210\/clinem\/dgab212","article-title":"Denosumab reduces lesional fluoride skeletal burden on na F-18 F PET-CT in patients with fibrous dysplasia\/McCune-Albright syndrome","volume":"106","author":"van der Bruggen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061619565620300_dgag154-B69","doi-asserted-by":"crossref","first-page":"115784","DOI":"10.1016\/j.bone.2020.115784","article-title":"Bisphosphonates for the treatment of fibrous dysplasia of bone","volume":"143","author":"Chapurlat","year":"2021","journal-title":"Bone"},{"issue":"12","key":"2026061619565620300_dgag154-B70","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1210\/jc.2018-02543","article-title":"Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates","volume":"104","author":"Majoor","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026061619565620300_dgag154-B71","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.4380","article-title":"Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study","volume":"36","author":"Meier","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2026061619565620300_dgag154-B72","doi-asserted-by":"crossref","first-page":"116819","DOI":"10.1016\/j.bone.2023.116819","article-title":"Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: a retrospective multicentric study","volume":"174","author":"Trojani","year":"2023","journal-title":"Bone"},{"issue":"49","key":"2026061619565620300_dgag154-B73","doi-asserted-by":"crossref","first-page":"e28138","DOI":"10.1097\/MD.0000000000028138","article-title":"Successful treatment with denosumab for pelvic fibrous dysplasia: a case report and review of the literature","volume":"100","author":"Ikuta","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2026061619565620300_dgag154-B74","doi-asserted-by":"crossref","first-page":"13855157","DOI":"10.3389\/fneur.2022.855157","article-title":"Case report: the imperfect association between craniofacial lesion burden and pain in fibrous dysplasia","volume":"13","author":"Golden","year":"2022","journal-title":"Front Neurol"},{"issue":"9","key":"2026061619565620300_dgag154-B75","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1210\/clinem\/dgae867","article-title":"Safety and efficacy of moderate-dose denosumab in fibrous dysplasia: observational results from a phase 2 clinical trial","volume":"110","author":"Szymczuk","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061619565620300_dgag154-B76","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjag037","article-title":"Effects of anti-RANKL, zoledronate or combination therapy in a mouse model of fibrous dysplasia: a preclinical study","author":"Palmisano","year":"2026","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026061619565620300_dgag154-B77","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jbspin.2014.04.013","article-title":"Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment","volume":"81","author":"Benhamou","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"6","key":"2026061619565620300_dgag154-B78","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1677\/JME-10-0097","article-title":"Skeletal progenitors and the GNAS gene: fibrous dysplasia of bone read through stem cells","volume":"45","author":"Riminucci","year":"2010","journal-title":"J Mol Endocrinol"},{"key":"2026061619565620300_dgag154-B79","first-page":"302","article-title":"Hemangiomatosis and its relation to massive osteolysis","volume":"67","author":"Gorham","year":"1954","journal-title":"Trans Assoc Am Physicians"},{"issue":"1","key":"2026061619565620300_dgag154-B80","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1530\/EOR-21-0083","article-title":"Current concepts from diagnosis to management in Gorham-Stout disease: a systematic narrative review of about 350 cases","volume":"7","author":"Angelini","year":"2022","journal-title":"EFORT Open Rev"},{"issue":"5","key":"2026061619565620300_dgag154-B81","doi-asserted-by":"crossref","first-page":"694","DOI":"10.5312\/wjo.v5.i5.694","article-title":"Vanishing bone disease (Gorham-Stout syndrome): a review of a rare entity","volume":"5","author":"Nikolaou","year":"2014","journal-title":"World J Orthop"},{"issue":"5","key":"2026061619565620300_dgag154-B82","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/path.989","article-title":"Cellular and humoral mechanisms of osteoclast formation and bone resorption in Gorham-Stout disease","volume":"195","author":"Hirayama","year":"2001","journal-title":"J Pathol"},{"issue":"13","key":"2026061619565620300_dgag154-B83","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2169\/internalmedicine.2118-18","article-title":"Fatal progression of Gorham-Stout disease with skull base osteomyelitis and lateral medullary syndrome","volume":"58","author":"Nozawa","year":"2019","journal-title":"Intern Med"},{"issue":"42","key":"2026061619565620300_dgag154-B84","doi-asserted-by":"crossref","first-page":"e8184","DOI":"10.1097\/MD.0000000000008184","article-title":"Mandibular Gorham-Stout disease: a case report and literature review","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2026061619565620300_dgag154-B85","doi-asserted-by":"crossref","first-page":"e0285","DOI":"10.2106\/JBJS.CC.18.00285","article-title":"Gorham-Stout syndrome of the shoulder girdle successfully controlled by antiresorptive agents: a report of 2 cases","volume":"9","author":"Matsumoto","year":"2019","journal-title":"JBJS Case Connect"},{"issue":"4","key":"2026061619565620300_dgag154-B86","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00198-023-06995-1","article-title":"Treatment for Gorham-Stout syndrome with a combination of teriparatide and denosumab","volume":"35","author":"Zhang","year":"2024","journal-title":"Osteoporos Int"},{"issue":"17","key":"2026061619565620300_dgag154-B87","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.3390\/ijerph17176174","article-title":"Hajdu-Cheney syndrome: a systematic review of the literature","volume":"17","author":"Cort\u00e9s-Mart\u00edn","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"2026061619565620300_dgag154-B88","doi-asserted-by":"crossref","first-page":"103650","DOI":"10.1016\/j.ejmg.2019.04.007","article-title":"Phenotypic presentations of Hajdu-Cheney syndrome according to age-5 distinct clinical presentations","volume":"63","author":"Graversen","year":"2020","journal-title":"Eur J Med Genet"},{"issue":"20","key":"2026061619565620300_dgag154-B89","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1128\/MCB.00299-08","article-title":"The association of Notch2 and NF-\u03baB accelerates RANKL-induced osteoclastogenesis","volume":"28","author":"Fukushima","year":"2008","journal-title":"Mol Cell Biol"},{"key":"2026061619565620300_dgag154-B90","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bone.2016.08.025","article-title":"Hajdu Cheney syndrome; report of a novel NOTCH2 mutation and treatment with denosumab","volume":"92","author":"Adami","year":"2016","journal-title":"Bone"},{"key":"2026061619565620300_dgag154-B91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2017.03.005","article-title":"Letter to the editor concerning \u201cHajdu Cheney syndrome; report of a novel NOTCH2 mutation and treatment with denosumab\u201d by G. Adami et al. Bone 2016;92:150-156","volume":"101","author":"Jerzakowski","year":"2017","journal-title":"Bone"},{"issue":"22","key":"2026061619565620300_dgag154-B92","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2026061619565620300_dgag154-B93","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/pbc.23166","article-title":"Reduced bone mineral density in adult patients with langerhans cell histiocytosis","volume":"58","author":"Makras","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2026061619565620300_dgag154-B94","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1084\/jem.20041785","article-title":"Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of langerhans cell histiocytosis","volume":"201","author":"da Costa","year":"2005","journal-title":"J Exp Med"},{"key":"2026061619565620300_dgag154-B95","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.metabol.2017.01.004","article-title":"Denosumab for the treatment of adult multisystem langerhans cell histiocytosis","volume":"69","author":"Makras","year":"2017","journal-title":"Metabolism"},{"issue":"7","key":"2026061619565620300_dgag154-B96","doi-asserted-by":"crossref","first-page":"E168","DOI":"10.1002\/ajh.26936","article-title":"Efficacy of denosumab monotherapy among adults with langerhans cell histiocytosis: a prospective clinical trial","volume":"98","author":"Makras","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"2026061619565620300_dgag154-B97","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00198-025-07538-6","article-title":"No overshoot of bone turnover after withdrawal of denosumab treatment of adults with langerhans cell histiocytosis: a prospective clinical trial","volume":"36","author":"Makras","year":"2025","journal-title":"Osteoporos Int"},{"key":"2026061619565620300_dgag154-B98","author":"Akhtar"},{"issue":"1","key":"2026061619565620300_dgag154-B99","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1186\/s12885-019-6072-8","article-title":"Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report","volume":"19","author":"Otani","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"2026061619565620300_dgag154-B100","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13256-018-1820-y","article-title":"Clinical improvement in a patient with monostotic melorheostosis after treatment with denosumab: a case report","volume":"12","author":"Byberg","year":"2018","journal-title":"J Med Case Rep"},{"issue":"12","key":"2026061619565620300_dgag154-B101","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1002\/ccr3.1894","article-title":"Treatment of diffuse sclerosing osteomyelitis of the jaw with denosumab shows remarkable results\u2014a report of two cases","volume":"6","author":"Hallmer","year":"2018","journal-title":"Clin Case Rep"},{"issue":"12","key":"2026061619565620300_dgag154-B102","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1093\/rheumatology\/kead276","article-title":"Follow-up imaging of SAPHO syndrome treated with denosumab","volume":"62","author":"Sakellariou","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2026061619565620300_dgag154-B103","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 years later: a narrative review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"2026061619565620300_dgag154-B104","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00223-025-01382-w","article-title":"Transition care for young persons with rare bone mineral conditions: a consensus recommendation from the ECTS rare bone disease action group","volume":"116","author":"Grasemann","year":"2025","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2026061619565620300_dgag154-B105","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00223-024-01256-7","article-title":"The role of the European reference network for rare bone diseases (ERN BOND) and European registries for rare bone and mineral conditions (EuRR-bone) in the governance of the management of rare bone and mineral diseases","volume":"115","author":"Priego Zurita","year":"2024","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"2026061619565620300_dgag154-B106","doi-asserted-by":"crossref","first-page":"104868","DOI":"10.1016\/j.ejmg.2023.104868","article-title":"Data collection on rare bone and mineral conditions in Europe: the landscape of registries and databases","volume":"66","author":"Priego Zurita","year":"2023","journal-title":"Eur J Med Genet"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag154\/67956230\/dgag154.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/e1760\/67956230\/dgag154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/e1760\/67956230\/dgag154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:57:16Z","timestamp":1781654236000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/7\/e1760\/8633048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":106,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4,7]]},"published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag154","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,7]]}}}